ASSOCIATION OF SNP CYP2C19 AND CLINICAL PARAMETERS IN RUSSIAN AND BURYAT PATIENTS AFTER TAKING CLOPIDOGREL AFTER CORONARY STENTING

Background. Clopidogrel is often used in patients undergoing coronary stenting for acute coronary syndrome. However, the CYP2C19 variants rs4244285(*2), rs4986893 (*3) affect the metabolism of clopidogrel. These alleles occur with different frequencies in patients of different nationalities, so the clopidogrel efficacy may differ in ethnic groups living in Russia. Objective. to assess the associations between genetic determinants of the risk of thrombotic complications during clopidogrel treatment and the clinical characteristics of Buryat and Russian patients, in order to search for personalized informative prognosis markers. Design and methods. The study included 142 Buryat and 150 Russian patients undergoing coronary stent placement for acute coronary syndrome. All patients received clopidogrel. Patients were stratified by the presence of CYP2C19*2, CYP2C19*3 alleles. In all patients efficacy endpoints were assessed, as well as corresponding therapy. Results. In Buryat patients CYP2C19*3 allele was significantly more common (11,6 % versus 1,3 %, p < 0,001) than in Russian. In Buryat patients, recurrence of anginal pain during exercise was associated with the CYP2C19*3 and/ or CYP2C19*2 genotypes (p = 0,015), as well as with the taking omeprazole (p = 0.015). In Russian patients, efficacy endpoints in clopidogrel treatment were associated with the presence of CYP2C19*2 and/or CYP2C19*3 alleles (p = 0.036). Conclusion. The presence of minor CYP2C19*3 and CYP2C19*2 alleles, along with the reports of recurrence of anginal pain during moderate and light exercise in Buryat patients may be considered as a prognostic sign of thrombotic complications.

1. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). European Heart Journal. 42(34). 2021; 3227–3337. https://doi.org/10.1093/eurheartj/ehab484

2. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 42(14), 2021; 1289–1367. https://doi.org/10.1093/eurheartj/ehaa575

3. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180(7):713–718. DOI:10.1503/cmaj.082001.

4. The volume of the official publication of the 2010 All-Russian Population Census. Volume 4. National composition and language proficiency, citizenship: 742–845. In Russian https://www.gks.ru/free_doc/new_site/perepis2010/croc/vol4pdf-m.html

5. Kitaeva EY, Shprakh VV, Mirzaev KB, et al. The frequency of CYP2C19 and ABCB1 polymorphisms associated with a change in the antiplatelet effect of clopidogrel is in Russians and Buryats. Siberian Medical Review. 2018; 3: 43–50. In Russian DOI:10.20333/2500136-2018-3-43-50

6. Zelenskaya EM, Lifshits GI, Nikolaev KY, et al. The frequency of the minor polymorphisms in the CYP2C19, VEGFR-2 genes and clinical outcomes in Russian and Buryat patients with acute coronary syndrome. Genetic Testing and Molecular Biomarkers. 2020; 24(6):338–342.

7. Tang H, Quertermous T, Rodriguez B. Genetic Structure, Self-Identified Race/Ethnicity, and Confounding in Case-Control Association Studies. American Journal of Human Genetics. 2005;76(2):268–275. DOI:10.1086/427888.

8. Subherwal S, Bach RG, Chen AY, et al. Baseline Risk of Major Bleeding in Non-ST-Segment — Elevation Myocardial Infarction The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score. Circulation. 2009; 119(14):1873–1882

9. Garcia-Garcia HM, McFadden EP, Farb A, et al. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation. 2018; 137(24):2635–2650. https://doi.org/10.1161/CIRCULATIONAHA.117.029289

10. Boytsov SA, Pogosova NV, Bubnov MG, et al. Cardiovascular prevention 2017. Russian national recommendations. Russian Journal of Cardiology 2018; 23 (6):7–122. In Russian http://dx.doi.org/10.15829/1560-4071-2018-6-7-122

11. Borinskaya SA, Kozlov AI, Yankovsky NK. Genes and food traditions. Ethnographicheskoje obozrenije. 2009; 3: 117–137 In Russian

12. Slepukhina AA, Zelenskaya EM, Lifshits GI. Genetic risk factors for vascular aging: molecular mechanisms, polymorphism of candidate genes and gene networks. Russian Journal of Cardiology. 2019; 10:78–85. In Russian https://doi.org/10.15829/1560-4071-2019-10-78-85

13. Mirzaev KB, Zelenskaya EM, Barbarash OL, et al. CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. Pharmgenomics. Pers Med. 2017; 10:107–114. https://doi.org/10.2147/PGPM.S126305

14. Zelenskaya EM, Nikolaev KY, Donirova OS, et al. Association between genetic determinants of clopidogel metabolism and clinical cardiovascular risk indicators in Buryat patients. Patologiya Krovoobrashcheniya i Kardiokhirurgiya, 2019; 23(3): 39–46. In Russian DOI:10.21688/1681-3472-2019-3-39-46

15. Knauer NY, Lifshits GI, Voronina EN, et al. Informativeness of genetic markers for optimizing personalized therapy with clopidogrel. Cardiologija. 2013; 53(8):72–75 In Russian

16. Mega JL, Simon T, Collet JP, et al. Reducedfunction CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304(16): 1821–30.